Company profile

New Limit

New Limit, founded in 2021, has raised approximately $240 million across Seed to latest funding rounds, including a $45 million round valuing the company at $1.6 billion. Headquartered in Boston, Massachusetts, United States, New Limit develops precision therapeutics using genomics and biomarker-driven approaches. Key investors include Kleiner Perkins. Since inception, the company has built a targeted therapy pipeline spanning oncology and metabolic disorders. With strong investor backing and advanced clinical programs, New Limit is positioned to expand its precision medicine platform and accelerate patient-focused treatment development.

Back to profiles

Quick facts

Total funding: $240 million
Founded: 2021

Notable investors

Kleiner Perkins

Reach buyers like New Limit on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like New Limit
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like New Limit.

The 14-day trial ships every feature, no card required.

Start free →